Evaxion announces business update and full year 2024 financial results
Provided By GlobeNewswire
Last update: Apr 1, 2025
COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financial results.
Read more at globenewswire.com
